Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2297-2306

  Beconi, Maria G ^a   Yates, Dawn ^b   Lyons, Kathryn ^a   Matthews, Kim ^b   Clifton, Steve ^b   Mead, Tania ^b   Prime, Michael ^c   Winkler, Dirk ^c,d   O'Connell, Catherine ^b   Walter, Daryl ^c,d   Toledo Sherman, Leticia ^a   Munoz Sanjuan, Ignacio ^a   Dominguez, Celia ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b BioFocus DPI   (United Kingdom)

^c EVOTEC UK LTD   (United Kingdom)

^d EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 5 (PIPERIDIN 1 YLMETHYL)THIAZOL 2YL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; DRUG METABOLITE; KYNURENINE 3 MONOOXYGENASE; OXYGENASE INHIBITOR; PLATINUM DICHLOROBIS(ISOPROPYLAMINE); PRODRUG; UNCLASSIFIED DRUG;

ACIDITY; AEROBIC METABOLISM; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD; DEALKYLATION; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG IMPURITY; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HUNTINGTON CHOREA; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANIMALS; AREA UNDER CURVE; CELL LINE; DOGS; HEPATOCYTES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; METABOLIC DETOXICATION, PHASE I; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; PRODRUGS; RATS; SULFONAMIDES; THIAZOLES;

MUS;

EID: 84869105177     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046532     Document Type: Article

References (13)

1. Baker JK and Little TL (1985) Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. J Med Chem 28:46-50.
2. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, and Giorgini F (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 21:961-966.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
4. Foster AC, Whetsell WO Jr, Bird ED, and Schwarcz R (1985) Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. Brain Res 336:207-214.
5. Lin G, Chu KW, Damani LA, Hawes EM, and Midha KK (1996) Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs. J Pharm Biomed Anal 14:727-738.
6. Muchowski PJ, Muchowski JM, Schwarcz R, and Guidetti P (2008), inventors; The J. David Gladstone Institutes, a Testamentary Trust Established under the Will of J. David Gladstone, University of Maryland, Muchowski PJ, Muchowski JM, Schwarcz R, and Guidetti P, assignees Small molecule inhibitors of kynurenine-3-monooxygenasepatent World Patent WO2008022281. 2008 Feb 21.
7. Pang KS and Kwan KC (1983) A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab Dispos 11:79-84.
8. Röver S, Cesura AM, Huguenin P, Kettler R, and Szente A (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40:4378-4385.
9. Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, and Schwarcz R (2010) Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem 113:1416-1425.
10. Schwarcz R, Guidetti P, Sathyasaikumar KV, and Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90:230-245.
11. Schwarcz R, Whetsell WO Jr, and Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316-318.
12. Testa B and Mayer JM (2003) Section 5.2.2: the hydrolysis of lactam metabolites, in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology, Wiley-VCH, New York.
13. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, et al. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863-874.